跳至主要内容
临床试验/EUCTR2015-001234-22-NL
EUCTR2015-001234-22-NL进行中(未招募)1 期

A randomized placebo-controlled study in patients with a Gallium-68 DOTATATE PET/CT positive, clinically non-functioning pituitary macroadenoma (NFMA) of the effect of Lanreotide autosolution on Tumor (adenoma) size - GALANT

Academic Medical Center0 个研究点目标入组 66 人开始时间: 2015年7月2日最近更新:
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
66

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • NFMA with suprasellar extension (in previously operated patients: residual adenoma or recurrence > 10 mm)
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 44
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 22

排除标准

  • Hypersensitivity for somatostatin or similar peptides
  • Optic chiasm compression with visual field defects (this is an operation indication)
  • Obstructive neuroendocrine gut tumor
  • Previous radiation therapy in the pituitary region
  • Symptomatic and proven cholelithiasis
  • Use of dopamine agonists in the past 6 months
  • Use of somatostatin analogues in the past 6 months
  • Pregnancy (plans)
  • Any contraindication to perform MRI with gadolinium-based contrast agent

研究者

发起方
Academic Medical Center

相似试验

The effect of lanreotide on non-functioning... | 临床试验